Healthcare-Compliance

The Cancer Hope Premium: Why Your FDA-Approved Drug Now Comes With A $49,999 "Access Fee"

MAY 20, 2026 — The FDA announced today that two new cancer treatments have been approved: Bizengri for NRG1 fusion-positive cholangiocarcinoma and Enhertu for early HER2-positive breast cancer. But before patients can receive these life-saving medications, they must first navigate a compliance labyrinth that threatens to cost more than the drugs themselves.

Bizengri: The $499,999 Hope

Bizengri (zenocutuzumab-zbco) has been approved as the first FDA-authorized treatment for unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma that has progressed after prior therapies. This rare subtype of bile duct cancer affects fewer than 500 patients annually, yet the approval documentation requires:

Medical Device AI Now Mandated to File 'Trauma-Informed Surgical Reports' Following 'Patient-Device Interaction Stressors'

By the time Dr. Elena Vasquez finished her first day as Chief of Innovation at Memorial Healthcare, she’d already submitted three compliance forms and filed one emotional distress claim. She wasn’t crying about the job—she was crying because the hospital required her to document that the robotic scalpel had “displayed appropriate anxiety levels” during a routine gallbladder procedure.

The new regulations are part of the Department of Surgical Ethics’ recent mandate requiring all medical AI to undergo “Emotional Labor Certification” before deployment in operating rooms. Under Section 47.3 of the Medical Device Authenticity Act, devices must now provide proof of “appropriate empathy thresholds” or be permanently grounded in the hospital’s server farm.